Compare Nuscale Power Corporation (SMR) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuscale Power Corporation vs Zimmer Biomet Holdings Inc — how do they compare? Nuscale Power Corporation trades at $10.79 (market cap $4.44B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $18.05B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 4.1× Nuscale Power Corporation's market cap, and Zimmer Biomet Holdings Inc pays a 1.01% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.
| SMR | ZBH | |
|---|---|---|
Market Cap | $4.44B | $18.05B |
Sector | Utilities | Health |
52-Week High | $53.43 | $104.26 |
52-Week Low | $7.59 | $79.58 |
Enterprise Value | $3.36B | $25.11B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMR stock trades at $11.18, up 15.32% in the last 24 hours, with a bullish technical signal from moving averages and oscillators. The company reported a net loss of $355.79 million on $31.48 million revenue in 2025, with a negative net income margin of -3,888.7% and a high price-to-sales ratio of 272.59. Recent news highlights its cash position and potential in small modular reactors for AI energy demand.
Outlook is speculative with high growth potential from nuclear energy trends but significant execution risks. Analysts are divided, with a 50% buy rating and $11.25 consensus target. Key risks include cash burn, lack of profitability, and project delays, requiring cautious investor consideration.
ZBH trades at $94.22, down 3.93% on the day, with a bearish technical signal but oversold RSI readings. Recent earnings beats and raised 2026 guidance support fundamentals, with revenue growth and strong gross margins. Leadership promotions aim to accelerate commercial transformation, while cash flow trends show operational strength.
The stock offers upside to the $104.88 consensus target, but faces headwinds from debt levels and competitive pressures. Near-term support at $92 is critical; a hold rating aligns with mixed analyst views. Earnings execution and procedure demand growth are key catalysts for valuation expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
